Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zimberelimab Optimization in Postoperative Cervical Cancer
NCT05872724Phase 2Recruiting
- Sponsor
- Affiliated Suzhou Hospital of Nanjing Medical University
- Start
- Jan 2023
- Primary completion
- Jan 2028
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of zimberelimab in Cervical Cancer (CC) (2 arms), sponsored by Affiliated Suzhou Hospital of Nanjing Medical University. Primary endpoint: Disease-Free Survival at 3 years. Started Jan 2023; status: recruiting.
02
Drugs
zimberelimab
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT05872724.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05872724.